{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T15:14:46Z","timestamp":1791213286353,"version":"4.1.0"},"reference-count":107,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,3,7]],"date-time":"2024-03-07T00:00:00Z","timestamp":1709769600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,3,7]],"date-time":"2024-03-07T00:00:00Z","timestamp":1709769600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100020258","name":"Department of Molecular Medicine, University of Pavia","doi-asserted-by":"publisher","award":["PRID-DMM"],"award-info":[{"award-number":["PRID-DMM"]}],"id":[{"id":"10.13039\/501100020258","id-type":"DOI","asserted-by":"publisher"}]},{"name":"STARS Grants programme, University of Padova","award":["WRAPS"],"award-info":[{"award-number":["WRAPS"]}]},{"DOI":"10.13039\/501100003407","name":"Ministero dell\u2019Istruzione, dell\u2019Universit\u00e0 e della Ricerca","doi-asserted-by":"publisher","award":["P2022Y2A3L"],"award-info":[{"award-number":["P2022Y2A3L"]}],"id":[{"id":"10.13039\/501100003407","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003500","name":"Universit\u00e0 degli Studi di Padova","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100003500","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Neurodegeneration"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Mutations in the \u03b2-glucocerebrosidase (<jats:italic>GBA1<\/jats:italic>) gene do cause the lysosomal storage Gaucher disease (GD) and are among the most frequent genetic risk factors for Parkinson\u2019s disease (PD). So far, studies on both neuronopathic GD and PD primarily focused on neuronal manifestations, besides the evaluation of microglial and astrocyte implication. White matter alterations were described in the central nervous system of paediatric type 1 GD patients and were suggested to sustain or even play a role in the PD process, although the contribution of oligodendrocytes has been so far scarcely investigated.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>We exploited a system to study the induction of central myelination in vitro, consisting of Oli-neu cells treated with dibutyryl-cAMP, in order to evaluate the expression levels and function of \u03b2-glucocerebrosidase during oligodendrocyte differentiation. Conduritol-B-epoxide, a \u03b2-glucocerebrosidase irreversible inhibitor was used to dissect the impact of \u03b2-glucocerebrosidase inactivation in the process of myelination, lysosomal degradation and \u03b1-synuclein accumulation in vitro. Moreover, to study the role of \u03b2-glucocerebrosidase in the white matter in vivo, we developed a novel mouse transgenic line in which \u03b2-glucocerebrosidase function is abolished in myelinating glia, by crossing the <jats:italic>Cnp1-cre<\/jats:italic> mouse line with a line bearing <jats:italic>loxP<\/jats:italic> sequences flanking <jats:italic>Gba1<\/jats:italic> exons 9\u201311, encoding for \u03b2-glucocerebrosidase catalytic domain. Immunofluorescence, western blot and lipidomic analyses were performed in brain samples from wild-type and knockout animals in order to assess the impact of genetic inactivation of \u03b2-glucocerebrosidase on myelination and on the onset of early neurodegenerative hallmarks, together with differentiation analysis in primary oligodendrocyte cultures.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Here we show that \u03b2-glucocerebrosidase inactivation in oligodendrocytes induces lysosomal dysfunction and inhibits myelination in vitro. Moreover, oligodendrocyte-specific \u03b2-glucocerebrosidase loss-of-function was sufficient to induce in vivo demyelination and early neurodegenerative hallmarks, including axonal degeneration, \u03b1-synuclein accumulation and astrogliosis, together with brain lipid dyshomeostasis and functional impairment.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Our study sheds light on the contribution of oligodendrocytes in GBA1-related diseases and supports the need for better\u00a0characterizing oligodendrocytes as actors playing a role in neurodegenerative diseases, also pointing at them as potential novel targets to set a brake to disease progression.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13024-024-00713-z","type":"journal-article","created":{"date-parts":[[2024,3,7]],"date-time":"2024-03-07T18:02:09Z","timestamp":1709834529000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":25,"title":["GBA1 inactivation in oligodendrocytes affects myelination and induces neurodegenerative hallmarks and lipid dyshomeostasis in mice"],"prefix":"10.1186","volume":"19","author":[{"given":"Ilaria","family":"Gregorio","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Loris","family":"Russo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enrica","family":"Torretta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pietro","family":"Barbacini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriella","family":"Contarini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giada","family":"Pacinelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dario","family":"Bizzotto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuela","family":"Moriggi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Braghetta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Papaleo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cecilia","family":"Gelfi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enrico","family":"Moro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7138-1857","authenticated-orcid":false,"given":"Matilde","family":"Cescon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,3,7]]},"reference":[{"key":"713_CR1","doi-asserted-by":"publisher","first-page":"441","DOI":"10.3390\/ijms18020441","volume":"18","author":"J Stirnemann","year":"2017","unstructured":"Stirnemann J, Belmatoug N, Camou F, Serratrice C, Froissart R, Caillaud C, et al. A Review of Gaucher Disease pathophysiology, clinical presentation and treatments. Int J Mol Sci. 2017;18:441.","journal-title":"Int J Mol Sci"},{"key":"713_CR2","unstructured":"Rosenbloom BE, Weinreb NJ. Gaucher Disease: a comprehensive review. Crit Rev Oncog [Internet]. 2013 [cited 2023 May 19];18. Available from: https:\/\/www.dl.begellhouse.com\/journals\/439f422d0783386a,0dc6d82859623d4b,3b64a9681182c9cf.html."},{"key":"713_CR3","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1159\/000440865","volume":"83","author":"A Dandana","year":"2015","unstructured":"Dandana A, Ben Khelifa S, Chahed H, Miled A, Ferchichi S. Gaucher Disease: clinical, biological and therapeutic aspects. Pathobiology. 2015;83:13\u201323.","journal-title":"Pathobiology"},{"key":"713_CR4","doi-asserted-by":"publisher","first-page":"1056","DOI":"10.1002\/jimd.12235","volume":"43","author":"R Schiffmann","year":"2020","unstructured":"Schiffmann R, Sevigny J, Rolfs A, Davies EH, Goker-Alpan O, Abdelwahab M, et al. The definition of neuronopathic Gaucher disease. J Inherit Metab Dis. 2020;43:1056\u20139.","journal-title":"J Inherit Metab Dis"},{"key":"713_CR5","first-page":"273","volume":"14","author":"E Sidransky","year":"2012","unstructured":"Sidransky E. Gaucher Disease: insights from a rare mendelian disorder. Discov Med. 2012;14:273\u201381.","journal-title":"Discov Med"},{"key":"713_CR6","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1002\/humu.9024","volume":"19","author":"E Orvisky","year":"2002","unstructured":"Orvisky E, Park J k, Parker A, Walker J m, Martin B m, Stubblefield B k, et al. The identification of eight novel glucocerebrosidase (GBA) mutations in patients with Gaucher disease. Hum Mutat. 2002;19:458\u20139.","journal-title":"Hum Mutat"},{"key":"713_CR7","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1016\/j.nbd.2003.08.016","volume":"14","author":"UH Schueler","year":"2003","unstructured":"Schueler UH, Kolter T, Kaneski CR, Blusztajn JK, Herkenham M, Sandhoff K, et al. Toxicity of glucosylsphingosine (glucopsychosine) to cultured neuronal cells: a model system for assessing neuronal damage in Gaucher disease type 2 and 3. Neurobiol Dis. 2003;14:595\u2013601.","journal-title":"Neurobiol Dis"},{"key":"713_CR8","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1016\/j.ymgme.2004.04.011","volume":"82","author":"K Wong","year":"2004","unstructured":"Wong K, Sidransky E, Verma A, Mixon T, Sandberg GD, Wakefield LK, et al. Neuropathology provides clues to the pathophysiology of Gaucher disease. Mol Genet Metab. 2004;82:192\u2013207.","journal-title":"Mol Genet Metab"},{"key":"713_CR9","doi-asserted-by":"publisher","first-page":"1375","DOI":"10.1093\/hmg\/ddr019","volume":"20","author":"T Farfel-Becker","year":"2011","unstructured":"Farfel-Becker T, Vitner EB, Pressey SNR, Eilam R, Cooper JD, Futerman AH. Spatial and temporal correlation between neuron loss and neuroinflammation in a mouse model of neuronopathic Gaucher disease. Hum Mol Genet. 2011;20:1375\u201386.","journal-title":"Hum Mol Genet"},{"key":"713_CR10","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1093\/hmg\/ddt468","volume":"23","author":"T Farfel-Becker","year":"2014","unstructured":"Farfel-Becker T, Vitner EB, Kelly SL, Bame JR, Duan J, Shinder V, et al. Neuronal accumulation of glucosylceramide in a mouse model of neuronopathic Gaucher disease leads to neurodegeneration. Hum Mol Genet. 2014;23:843\u201354.","journal-title":"Hum Mol Genet"},{"key":"713_CR11","doi-asserted-by":"crossref","unstructured":"Stoker TB, Torsney KM, Barker RA. Pathological mechanisms and clinical aspects of GBA1 mutation-associated Parkinson\u2019s Disease. In: Stoker TB, Greenland JC, editors. Park Dis Pathog Clin Asp [Internet]. Brisbane (AU): Codon Publications; 2018 [cited 2023 Feb 20]. Available from: http:\/\/www.ncbi.nlm.nih.gov\/books\/NBK536716\/","DOI":"10.15586\/codonpublications.parkinsonsdisease.2018.ch3"},{"key":"713_CR12","doi-asserted-by":"crossref","first-page":"7","DOI":"10.17650\/2073-8803-2018-13-4-7-22","volume":"13","author":"MR Alaei","year":"2019","unstructured":"Alaei MR, Tabrizi A, Jafari N, Mozafari H. Gaucher Disease: new expanded classification emphasizing neurological features. Iran J Child Neurol. 2019;13:7\u201324.","journal-title":"Iran J Child Neurol"},{"key":"713_CR13","doi-asserted-by":"publisher","first-page":"2277","DOI":"10.1212\/01.wnl.0000304039.11891.29","volume":"70","author":"Z Gan-Or","year":"2008","unstructured":"Gan-Or Z, Giladi N, Rozovski U, Shifrin C, Rosner S, Gurevich T, et al. Genotype-phenotype correlations between GBA mutations and Parkinson disease risk and onset. Neurology. 2008;70:2277\u201383.","journal-title":"Neurology"},{"key":"713_CR14","doi-asserted-by":"publisher","first-page":"2150","DOI":"10.1002\/mds.28232","volume":"35","author":"S Blumenreich","year":"2020","unstructured":"Blumenreich S, Jenkins BJ, Barav OB, Milenkovic I, Futerman AH. The Lysosome and Nonmotor Symptoms: linking Parkinson\u2019s Disease and lysosomal storage disorders. Mov Disord. 2020;35:2150\u20135.","journal-title":"Mov Disord"},{"key":"713_CR15","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.nbd.2018.03.008","volume":"122","author":"C Pitcairn","year":"2019","unstructured":"Pitcairn C, Wani WY, Mazzulli JR. Dysregulation of the autophagic-lysosomal pathway in Gaucher and Parkinson\u2019s disease. Neurobiol Dis. 2019;122:72\u201382.","journal-title":"Neurobiol Dis"},{"key":"713_CR16","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1016\/j.cmet.2013.04.014","volume":"17","author":"LD Osellame","year":"2013","unstructured":"Osellame LD, Rahim AA, Hargreaves IP, Gegg ME, Richard-Londt A, Brandner S, et al. Mitochondria and quality control defects in a mouse model of Gaucher Disease\u2014Links to Parkinson\u2019s Disease. Cell Metab. 2013;17:941\u201353.","journal-title":"Cell Metab"},{"key":"713_CR17","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1089\/ars.2015.6307","volume":"23","author":"EM Rocha","year":"2015","unstructured":"Rocha EM, Smith GA, Park E, Cao H, Graham A-R, Brown E, et al. Sustained systemic glucocerebrosidase inhibition induces brain \u03b1-synuclein aggregation, microglia and complement C1q activation in mice. Antioxid Redox Signal. 2015;23:550\u201364.","journal-title":"Antioxid Redox Signal"},{"key":"713_CR18","doi-asserted-by":"publisher","first-page":"5775","DOI":"10.1093\/hmg\/ddv297","volume":"24","author":"O Awad","year":"2015","unstructured":"Awad O, Sarkar C, Panicker LM, Miller D, Zeng X, Sgambato JA, et al. Altered TFEB-mediated lysosomal biogenesis in Gaucher disease iPSC-derived neuronal cells. Hum Mol Genet. 2015;24:5775\u201388.","journal-title":"Hum Mol Genet"},{"key":"713_CR19","doi-asserted-by":"publisher","first-page":"4028","DOI":"10.1038\/ncomms5028","volume":"5","author":"DC Sch\u00f6ndorf","year":"2014","unstructured":"Sch\u00f6ndorf DC, Aureli M, McAllister FE, Hindley CJ, Mayer F, Schmid B, et al. iPSC-derived neurons from GBA1-associated Parkinson\u2019s disease patients show autophagic defects and impaired calcium homeostasis. Nat Commun. 2014;5:4028.","journal-title":"Nat Commun"},{"key":"713_CR20","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.cell.2011.06.001","volume":"146","author":"JR Mazzulli","year":"2011","unstructured":"Mazzulli JR, Xu Y-H, Sun Y, Knight AL, McLean PJ, Caldwell GA, et al. Gaucher\u2019s Disease Glucocerebrosidase and <alpha>-synuclein form a bidirectional pathogenic loop in synucleinopathies. Cell. 2011;146:37\u201352.","journal-title":"Cell"},{"key":"713_CR21","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1002\/mds.23732","volume":"26","author":"AH Schapira","year":"2011","unstructured":"Schapira AH, Jenner P. Etiology and pathogenesis of Parkinson\u2019s disease. Mov Disord. 2011;26:1049\u201355.","journal-title":"Mov Disord"},{"key":"713_CR22","doi-asserted-by":"publisher","first-page":"2603","DOI":"10.1093\/hmg\/ddx120","volume":"26","author":"FN Soria","year":"2017","unstructured":"Soria FN, Engeln M, Martinez-Vicente M, Glangetas C, L\u00f3pez-Gonz\u00e1lez MJ, Dovero S, et al. Glucocerebrosidase deficiency in dopaminergic neurons induces microglial activation without neurodegeneration. Hum Mol Genet. 2017;26:2603\u201315.","journal-title":"Hum Mol Genet"},{"key":"713_CR23","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1007\/BF00690463","volume":"65","author":"NG Conradi","year":"1984","unstructured":"Conradi NG, Sourander P, Nilsson O, Svennerholm L, Erikson A. Neuropathology of the Norrbottnian type of Gaucher disease. Acta Neuropathol (Berl). 1984;65:99\u2013109.","journal-title":"Acta Neuropathol (Berl)"},{"key":"713_CR24","doi-asserted-by":"publisher","first-page":"442","DOI":"10.3389\/fnins.2020.00442","volume":"14","author":"A Sanyal","year":"2020","unstructured":"Sanyal A, Novis HS, Gasser E, Lin S, LaVoie MJ. LRRK2 kinase inhibition rescues deficits in lysosome function due to heterozygous GBA1 expression in human iPSC-derived neurons. Front Neurosci. 2020;14:442.","journal-title":"Front Neurosci"},{"key":"713_CR25","doi-asserted-by":"publisher","DOI":"10.1016\/j.nbd.2019.104647","volume":"134","author":"E Aflaki","year":"2020","unstructured":"Aflaki E, Stubblefield BK, McGlinchey RP, McMahon B, Ory DS, Sidransky E. A characterization of Gaucher iPS-derived astrocytes: Potential implications for Parkinson\u2019s disease. Neurobiol Dis. 2020;134: 104647.","journal-title":"Neurobiol Dis"},{"key":"713_CR26","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1186\/s12974-021-02272-2","volume":"18","author":"E Brunialti","year":"2021","unstructured":"Brunialti E, Villa A, Mekhaeil M, Mornata F, Vegeto E, Maggi A, et al. Inhibition of microglial \u03b2-glucocerebrosidase hampers the microglia-mediated antioxidant and protective response in neurons. J Neuroinflammation. 2021;18:220.","journal-title":"J Neuroinflammation"},{"key":"713_CR27","first-page":"e79830","volume":"11","author":"CS Boddupalli","year":"2022","unstructured":"Boddupalli CS, Nair S, Belinsky G, Gans J, Teeple E, Nguyen T-H, et al. Neuroinflammation in neuronopathic Gaucher disease: Role of microglia and NK cells, biomarkers, and response to substrate reduction therapy. Zaidi M, editor eLife. 2022;11:e79830.","journal-title":"Zaidi M, editor. eLife"},{"key":"713_CR28","doi-asserted-by":"crossref","unstructured":"Wang L, Lin G, Zuo Z, Li Y, Byeon SK, Pandey A, et al. Neuronal activity induces glucosylceramide that is secreted via exosomes for lysosomal degradation in glia. Sci Adv. 8:eabn3326.","DOI":"10.1126\/sciadv.abn3326"},{"key":"713_CR29","doi-asserted-by":"publisher","first-page":"1424","DOI":"10.3390\/cells8111424","volume":"8","author":"S Kuhn","year":"2019","unstructured":"Kuhn S, Gritti L, Crooks D, Dombrowski Y. Oligodendrocytes in development, myelin generation and beyond. Cells. 2019;8:1424.","journal-title":"Cells"},{"key":"713_CR30","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1038\/s41467-022-28720-y","volume":"13","author":"M Meschkat","year":"2022","unstructured":"Meschkat M, Steyer AM, Weil M-T, Kusch K, Jahn O, Piepkorn L, et al. White matter integrity in mice requires continuous myelin synthesis at the inner tongue. Nat Commun. 2022;13:1163.","journal-title":"Nat Commun"},{"key":"713_CR31","doi-asserted-by":"publisher","first-page":"1241","DOI":"10.1111\/joa.13577","volume":"239","author":"JM Edgar","year":"2021","unstructured":"Edgar JM, McGowan E, Chapple KJ, M\u00f6bius W, Lemgruber L, Insall RH, et al. R\u00edo-Hortega\u2019s drawings revisited with fluorescent protein defines a cytoplasm-filled channel system of CNS myelin. J Anat. 2021;239:1241\u201355.","journal-title":"J Anat"},{"key":"713_CR32","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.ejrad.2018.02.014","volume":"102","author":"H Kang","year":"2018","unstructured":"Kang H, Zhang M, Ouyang M, Guo R, Yu Q, Peng Q, et al. Brain white matter microstructural alterations in children of type I Gaucher disease characterized with diffusion tensor MR imaging. Eur J Radiol. 2018;102:22\u20139.","journal-title":"Eur J Radiol"},{"key":"713_CR33","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1007\/s10545-011-9288-6","volume":"34","author":"EH Davies","year":"2011","unstructured":"Davies EH, Seunarine KK, Banks T, Clark CA, Vellodi A. Brain white matter abnormalities in paediatric Gaucher Type I and Type III using diffusion tensor imaging. J Inherit Metab Dis. 2011;34:549\u201353.","journal-title":"J Inherit Metab Dis"},{"key":"713_CR34","unstructured":"Aronson SM, Volk BW. Cerebral Sphingolipidoses: a symposium on Tay-Sachs\u2019 Disease and allied disorders. Elsevier; 2013. p. 1\u2013474.\u00a0ISBN: 9781483221519."},{"key":"713_CR35","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1038\/nrneurol.2011.21","volume":"7","author":"NI Bohnen","year":"2011","unstructured":"Bohnen NI, Albin RL. White matter lesions in Parkinson disease. Nat Rev Neurol. 2011;7:229\u201336.","journal-title":"Nat Rev Neurol"},{"key":"713_CR36","doi-asserted-by":"publisher","first-page":"13819","DOI":"10.1073\/pnas.0606016103","volume":"103","author":"IB Enquist","year":"2006","unstructured":"Enquist IB, Nilsson E, Ooka A, M\u00e5nsson J-E, Olsson K, Ehinger M, et al. Effective cell and gene therapy in a murine model of Gaucher disease. Proc Natl Acad Sci U S A. 2006;103:13819\u201324.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"713_CR37","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1038\/ng1095","volume":"33","author":"C Lappe-Siefke","year":"2003","unstructured":"Lappe-Siefke C, Goebbels S, Gravel M, Nicksch E, Lee J, Braun PE, et al. Disruption of Cnp1 uncouples oligodendroglial functions in axonal support and myelination. Nat Genet. 2003;33:366\u201374.","journal-title":"Nat Genet"},{"key":"713_CR38","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.1096\/fj.13-239533","volume":"28","author":"P Chen","year":"2014","unstructured":"Chen P, Cescon M, Megighian A, Ronaldo P. Collagen VI regulates peripheral nerve myelination and function. FASEB J. 2014;28:1145\u201356.","journal-title":"FASEB J"},{"key":"713_CR39","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1111\/j.1460-9568.1995.tb01115.x","volume":"7","author":"M Jung","year":"1995","unstructured":"Jung M, Kr\u00e4mer E, Grzenkowski M, Tang K, Blakemore W, Aguzzi A, et al. Lines of murine oligodendroglial precursor cells immortalized by an activated neu tyrosine kinase show distinct degrees of interaction with axons in vitro and in vivo. Eur J Neurosci. 1995;7:1245\u201365.","journal-title":"Eur J Neurosci"},{"key":"713_CR40","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1002\/jnr.490220402","volume":"22","author":"J Trotter","year":"1989","unstructured":"Trotter J, Bitter-Suermann D, Schachner M. Differentiation-regulated loss of the polysialylated embryonic form and expression of the different polypeptides of the neural cell adhesion molecule by cultured oligodendrocytes and myelin. J Neurosci Res. 1989;22:369\u201383.","journal-title":"J Neurosci Res"},{"key":"713_CR41","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1002\/glia.23266","volume":"66","author":"L Zoupi","year":"2018","unstructured":"Zoupi L, Savvaki M, Kalemaki K, Kalafatakis I, Sidiropoulou K, Karagogeos D. The function of contactin-2\/TAG-1 in oligodendrocytes in health and demyelinating pathology. Glia. 2018;66:576\u201391.","journal-title":"Glia"},{"key":"713_CR42","doi-asserted-by":"publisher","first-page":"14211","DOI":"10.1038\/srep14211","volume":"5","author":"A Sasaki","year":"2015","unstructured":"Sasaki A, Arawaka S, Sato H, Kato T. Sensitive western blotting for detection of endogenous Ser129-phosphorylated \u03b1-synuclein in intracellular and extracellular spaces. Sci Rep. 2015;5:14211.","journal-title":"Sci Rep"},{"key":"713_CR43","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1007\/978-1-4939-7862-5_2","volume-title":"Myelin Methods Protoc","author":"M Thetiot","year":"2018","unstructured":"Thetiot M, Freeman SA, Desmazi\u00e8res A. Immunohistochemical analysis of myelin structures. In: Woodhoo A, editor. Myelin Methods Protoc. New York, NY: Springer; 2018. p. 15\u201323."},{"key":"713_CR44","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1038\/nn.4258","volume":"19","author":"D He","year":"2016","unstructured":"He D, Marie C, Zhao C, Kim B, Wang J, Deng Y, et al. Chd7 Cooperates with Sox10 and Regulates the Onset of CNS Myelination and Remyelination. Nat Neurosci. 2016;19:678\u201389.","journal-title":"Nat Neurosci"},{"key":"713_CR45","doi-asserted-by":"publisher","first-page":"3606","DOI":"10.1038\/s41598-019-40342-x","volume":"9","author":"O de Faria","year":"2019","unstructured":"de Faria O, Dhaunchak AS, Kamen Y, Roth AD, Kuhlmann T, Colman DR, et al. TMEM10 promotes oligodendrocyte differentiation and is expressed by oligodendrocytes in human remyelinating multiple sclerosis plaques. Sci Rep. 2019;9:3606.","journal-title":"Sci Rep"},{"key":"713_CR46","doi-asserted-by":"publisher","first-page":"15355","DOI":"10.1523\/JNEUROSCI.3005-09.2009","volume":"29","author":"LM Prolo","year":"2009","unstructured":"Prolo LM, Vogel H, Reimer RJ. The lysosomal sialic acid transporter sialin is required for normal CNS myelination. J Neurosci. 2009;29:15355\u201365.","journal-title":"J Neurosci"},{"key":"713_CR47","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1002\/glia.23274","volume":"66","author":"N Garc\u00eda-Mateo","year":"2018","unstructured":"Garc\u00eda-Mateo N, Pascua-Maestro R, P\u00e9rez-Castellanos A, Lillo C, Sanchez D, Ganfornina MD. Myelin extracellular leaflet compaction requires apolipoprotein D membrane management to optimize lysosomal-dependent recycling and glycocalyx removal. Glia. 2018;66:670\u201387.","journal-title":"Glia"},{"key":"713_CR48","doi-asserted-by":"publisher","first-page":"3432","DOI":"10.1093\/hmg\/ddw185","volume":"25","author":"J Magalhaes","year":"2016","unstructured":"Magalhaes J, Gegg ME, Migdalska-Richards A, Doherty MK, Whitfield PD, Schapira AHV. Autophagic lysosome reformation dysfunction in glucocerebrosidase deficient cells: relevance to Parkinson disease. Hum Mol Genet. 2016;25:3432\u201345.","journal-title":"Hum Mol Genet"},{"key":"713_CR49","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1007\/s00441-017-2704-y","volume":"373","author":"I Stojkovska","year":"2018","unstructured":"Stojkovska I, Krainc D, Mazzulli JR. Molecular mechanisms of \u03b1-synuclein and GBA1 in Parkinson\u2019s Disease. Cell Tissue Res. 2018;373:51\u201360.","journal-title":"Cell Tissue Res"},{"key":"713_CR50","doi-asserted-by":"publisher","first-page":"11929","DOI":"10.1523\/JNEUROSCI.1860-14.2014","volume":"34","author":"Y Zhang","year":"2014","unstructured":"Zhang Y, Chen K, Sloan SA, Bennett ML, Scholze AR, O\u2019Keeffe S, et al. An RNA-Sequencing transcriptome and splicing database of glia, neurons, and vascular cells of the cerebral cortex. J Neurosci. 2014;34:11929\u201347.","journal-title":"J Neurosci"},{"key":"713_CR51","doi-asserted-by":"publisher","first-page":"964","DOI":"10.1002\/glia.22653","volume":"62","author":"YT Asi","year":"2014","unstructured":"Asi YT, Simpson JE, Heath PR, Wharton SB, Lees AJ, Revesz T, et al. Alpha-synuclein mRNA expression in oligodendrocytes in MSA. Glia. 2014;62:964\u201370.","journal-title":"Glia"},{"key":"713_CR52","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1016\/j.ymgme.2007.08.001","volume":"92","author":"LK Hein","year":"2007","unstructured":"Hein LK, Meikle PJ, Hopwood JJ, Fuller M. Secondary sphingolipid accumulation in a macrophage model of Gaucher disease. Mol Genet Metab. 2007;92:336\u201345.","journal-title":"Mol Genet Metab"},{"key":"713_CR53","doi-asserted-by":"publisher","first-page":"1409","DOI":"10.1002\/mds.27119","volume":"32","author":"P Garc\u00eda-Sanz","year":"2017","unstructured":"Garc\u00eda-Sanz P, Orgaz L, Bueno-Gil G, Espadas I, Rodr\u00edguez-Traver E, Kulisevsky J, et al. N370S-GBA1 mutation causes lysosomal cholesterol accumulation in Parkinson\u2019s disease. Mov Disord. 2017;32:1409\u201322.","journal-title":"Mov Disord"},{"key":"713_CR54","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.neuron.2016.05.018","volume":"91","author":"M Bacioglu","year":"2016","unstructured":"Bacioglu M, Maia LF, Preische O, Schelle J, Apel A, Kaeser SA, et al. Neurofilament light chain in blood and CSF as marker of disease progression in mouse models and in neurodegenerative diseases. Neuron. 2016;91:56\u201366.","journal-title":"Neuron"},{"key":"713_CR55","doi-asserted-by":"publisher","first-page":"24","DOI":"10.3389\/fncel.2017.00024","volume":"11","author":"S J\u00e4kel","year":"2017","unstructured":"J\u00e4kel S, Dimou L. Glial cells and their function in the adult brain: a journey through the history of their ablation. Front Cell Neurosci. 2017;11:24.","journal-title":"Front Cell Neurosci"},{"key":"713_CR56","doi-asserted-by":"crossref","unstructured":"Montero-Odasso M, Pieruccini-Faria F, Bartha R, Black SE, Finger E, Freedman M, et al. Motor phenotype in neurodegenerative disorders: gait and balance platform study design protocol for the ontario neurodegenerative research initiative (ONDRI).\u00a0J Alzheimer Dis. 2017;59:707\u201321.","DOI":"10.3233\/JAD-170149"},{"key":"713_CR57","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1002\/mds.24945","volume":"27","author":"A McNeill","year":"2012","unstructured":"McNeill A, Duran R, Proukakis C, Bras J, Hughes D, Mehta A, et al. Hyposmia and cognitive impairment in Gaucher Disease patients and carriers. Mov Disord Off J Mov Disord Soc. 2012;27:526\u201332.","journal-title":"Mov Disord Off J Mov Disord Soc"},{"key":"713_CR58","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1002\/ana.23614","volume":"72","author":"ME Gegg","year":"2012","unstructured":"Gegg ME, Burke D, Heales SJR, Cooper JM, Hardy J, Wood NW, et al. Glucocerebrosidase deficiency in substantia nigra of Parkinson Disease brains. Ann Neurol. 2012;72:455\u201363.","journal-title":"Ann Neurol"},{"key":"713_CR59","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41531-021-00272-w","volume":"8","author":"A Navarro-Romero","year":"2022","unstructured":"Navarro-Romero A, Fernandez-Gonzalez I, Riera J, Montpeyo M, Albert-Bayo M, Lopez-Royo T, et al. Lysosomal lipid alterations caused by glucocerebrosidase deficiency promote lysosomal dysfunction, chaperone-mediated-autophagy deficiency, and alpha-synuclein pathology. Npj Park Dis. 2022;8:1\u201315.","journal-title":"Npj Park Dis"},{"key":"713_CR60","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1083\/jcb.200509022","volume":"172","author":"K Trajkovic","year":"2006","unstructured":"Trajkovic K, Dhaunchak AS, Goncalves JT, Wenzel D, Schneider A, Bunt G, et al. Neuron to glia signaling triggers myelin membrane exocytosis from endosomal storage sites. J Cell Biol. 2006;172:937\u201348.","journal-title":"J Cell Biol"},{"key":"713_CR61","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1242\/jcs.022731","volume":"121","author":"C Winterstein","year":"2008","unstructured":"Winterstein C, Trotter J, Kr\u00e4mer-Albers E-M. Distinct endocytic recycling of myelin proteins promotes oligodendroglial membrane remodeling. J Cell Sci. 2008;121:834\u201342.","journal-title":"J Cell Sci"},{"key":"713_CR62","doi-asserted-by":"publisher","first-page":"1745","DOI":"10.1002\/glia.23646","volume":"67","author":"AN Bankston","year":"2019","unstructured":"Bankston AN, Forston MD, Howard RM, Andres KR, Smith AE, Ohri SS, et al. Autophagy is essential for oligodendrocyte differentiation, survival, and proper myelination. Glia. 2019;67:1745\u201359.","journal-title":"Glia"},{"key":"713_CR63","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1097\/00005072-199909000-00001","volume":"58","author":"RD Folkerth","year":"1999","unstructured":"Folkerth RD. Abnormalities of developing white matter in lysosomal storage diseases. J Neuropathol Exp Neurol. 1999;58:887\u2013902.","journal-title":"J Neuropathol Exp Neurol"},{"key":"713_CR64","first-page":"1","volume":"2","author":"CR Ferreira","year":"2017","unstructured":"Ferreira CR, Gahl WA. Lysosomal storage diseases. Transl Sci Rare Dis. 2017;2:1.","journal-title":"Transl Sci Rare Dis"},{"key":"713_CR65","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1111\/jnc.15773","volume":"165","author":"LK Festa","year":"2023","unstructured":"Festa LK, Clyde AE, Long CC, Roth LM, Grinspan JB, Jordan-Sciutto KL. Antiretroviral treatment reveals a novel role for lysosomes in oligodendrocyte maturation. J Neurochem. 2023;165:722\u201340.","journal-title":"J Neurochem"},{"key":"713_CR66","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1038\/s41586-022-05439-w","volume":"611","author":"JW Blanchard","year":"2022","unstructured":"Blanchard JW, Akay LA, Davila-Velderrain J, von Maydell D, Mathys H, Davidson SM, et al. APOE4 impairs myelination via cholesterol dysregulation in oligodendrocytes. Nature. 2022;611:769\u201379.","journal-title":"Nature"},{"key":"713_CR67","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1016\/j.stemcr.2015.07.002","volume":"5","author":"M Djelloul","year":"2015","unstructured":"Djelloul M, Holmqvist S, Boza-Serrano A, Azevedo C, Yeung MS, Goldwurm S, et al. Alpha-synuclein expression in the oligodendrocyte lineage: an in vitro and in vivo study using rodent and human models. stem cell Rep. 2015;5:174.","journal-title":"stem cell Rep"},{"key":"713_CR68","doi-asserted-by":"publisher","first-page":"2357","DOI":"10.1016\/j.neurobiolaging.2014.02.028","volume":"35","author":"VEL May","year":"2014","unstructured":"May VEL, Ettle B, Poehler A-M, Nuber S, Ubhi K, Rockenstein E, et al. \u03b1-Synuclein impairs oligodendrocyte progenitor maturation in multiple system atrophy. Neurobiol Aging. 2014;35:2357\u201368.","journal-title":"Neurobiol Aging"},{"key":"713_CR69","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1016\/j.stemcr.2017.12.001","volume":"10","author":"S Kaji","year":"2018","unstructured":"Kaji S, Maki T, Kinoshita H, Uemura N, Ayaki T, Kawamoto Y, et al. Pathological endogenous \u03b1-synuclein accumulation in oligodendrocyte precursor cells potentially induces inclusions in multiple system atrophy. Stem Cell Rep. 2018;10:356\u201365.","journal-title":"Stem Cell Rep"},{"key":"713_CR70","doi-asserted-by":"publisher","first-page":"1888","DOI":"10.1523\/JNEUROSCI.3809-03.2004","volume":"24","author":"H-J Lee","year":"2004","unstructured":"Lee H-J, Khoshaghideh F, Patel S, Lee S-J. Clearance of \u03b1-Synuclein oligomeric intermediates via the lysosomal degradation pathway. J Neurosci. 2004;24:1888\u201396.","journal-title":"J Neurosci"},{"key":"713_CR71","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1038\/s41419-023-05672-9","volume":"14","author":"P Calabresi","year":"2023","unstructured":"Calabresi P, Mechelli A, Natale G, Volpicelli-Daley L, Di Lazzaro G, Ghiglieri V. Alpha-synuclein in Parkinson\u2019s disease and other synucleinopathies: from overt neurodegeneration back to early synaptic dysfunction. Cell Death Dis. 2023;14:176.","journal-title":"Cell Death Dis"},{"key":"713_CR72","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.mcn.2014.06.012","volume":"0","author":"B Ettle","year":"2014","unstructured":"Ettle B, Reiprich S, Deusser J, Schlachetzki JCM, Xiang W, Prots I, et al. Intracellular alpha-synuclein affects early maturation of primary oligodendrocyte progenitor cells. Mol Cell Neurosci. 2014;0:68\u201378.","journal-title":"Mol Cell Neurosci"},{"key":"713_CR73","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1002\/mds.25397","volume":"28","author":"F Agosta","year":"2013","unstructured":"Agosta F, Kostic VS, Davidovic K, Kresojevi\u0107 N, Sarro L, Svetel M, et al. White matter abnormalities in Parkinson\u2019s disease patients with glucocerebrosidase gene mutations. Mov Disord. 2013;28:772\u20138.","journal-title":"Mov Disord"},{"key":"713_CR74","doi-asserted-by":"publisher","first-page":"682","DOI":"10.3174\/ajnr.A2372","volume":"32","author":"SH Lee","year":"2011","unstructured":"Lee SH, Kim SS, Tae WS, Lee SY, Choi JW, Koh SB, et al. Regional volume analysis of the Parkinson Disease brain in early disease stage: gray matter, white matter, striatum, and thalamus. AJNR Am J Neuroradiol. 2011;32:682\u20137.","journal-title":"AJNR Am J Neuroradiol"},{"key":"713_CR75","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1002\/hbm.21245","volume":"33","author":"T Hattori","year":"2011","unstructured":"Hattori T, Orimo S, Aoki S, Ito K, Abe O, Amano A, et al. Cognitive status correlates with white matter alteration in Parkinson\u2019s disease. Hum Brain Mapp. 2011;33:727\u201339.","journal-title":"Hum Brain Mapp"},{"key":"713_CR76","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1002\/mds.26312","volume":"31","author":"GW Duncan","year":"2016","unstructured":"Duncan GW, Firbank MJ, Yarnall AJ, Khoo TK, Brooks DJ, Barker RA, et al. Gray and white matter imaging: a biomarker for cognitive impairment in early Parkinson\u2019s disease? Mov Disord. 2016;31:103\u201310.","journal-title":"Mov Disord"},{"key":"713_CR77","doi-asserted-by":"publisher","first-page":"1610","DOI":"10.1126\/science.280.5369.1610","volume":"280","author":"I Griffiths","year":"1998","unstructured":"Griffiths I, Klugmann M, Anderson T, Yool D, Thomson C, Schwab MH, et al. Axonal swellings and degeneration in mice lacking the major proteolipid of myelin. Science. 1998;280:1610\u20133.","journal-title":"Science"},{"key":"713_CR78","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1038\/nature11007","volume":"485","author":"U F\u00fcnfschilling","year":"2012","unstructured":"F\u00fcnfschilling U, Supplie LM, Mahad D, Boretius S, Saab AS, Edgar J, et al. Glycolytic oligodendrocytes maintain myelin and long-term axonal integrity. Nature. 2012;485:517\u201321.","journal-title":"Nature"},{"key":"713_CR79","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1038\/nature11314","volume":"487","author":"Y Lee","year":"2012","unstructured":"Lee Y, Morrison BM, Li Y, Lengacher S, Farah MH, Hoffman PN, et al. Oligodendroglia metabolically support axons and contribute to neurodegeneration. Nature. 2012;487:443\u20138.","journal-title":"Nature"},{"key":"713_CR80","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1016\/j.bbrc.2018.03.042","volume":"504","author":"M Fuller","year":"2018","unstructured":"Fuller M, Futerman AH. The brain lipidome in neurodegenerative lysosomal storage disorders. Biochem Biophys Res Commun. 2018;504:623\u20138.","journal-title":"Biochem Biophys Res Commun"},{"key":"713_CR81","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41531-022-00430-8","volume":"9","author":"CEG Leyns","year":"2023","unstructured":"Leyns CEG, Prigent A, Beezhold B, Yao L, Hatcher NG, Tao P, et al. Glucocerebrosidase activity and lipid levels are related to protein pathologies in Parkinson\u2019s disease. Npj Park Dis. 2023;9:1\u201314.","journal-title":"Npj Park Dis"},{"key":"713_CR82","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1523\/JNEUROSCI.0680-22.2022","volume":"43","author":"CL Mahoney-Crane","year":"2023","unstructured":"Mahoney-Crane CL, Viswanathan M, Russell D, Curtiss RAC, Freire J, Bobba SS, et al. Neuronopathic GBA1L444P mutation accelerates glucosylsphingosine levels and formation of hippocampal alpha-synuclein inclusions. J Neurosci. 2023;43:501\u201321.","journal-title":"J Neurosci"},{"key":"713_CR83","doi-asserted-by":"publisher","first-page":"9617","DOI":"10.1523\/JNEUROSCI.1525-17.2017","volume":"37","author":"YV Taguchi","year":"2017","unstructured":"Taguchi YV, Liu J, Ruan J, Pacheco J, Zhang X, Abbasi J, et al. Glucosylsphingosine promotes \u03b1-synuclein pathology in mutant GBA-associated Parkinson\u2019s Disease. J Neurosci. 2017;37:9617\u201331.","journal-title":"J Neurosci"},{"key":"713_CR84","doi-asserted-by":"publisher","first-page":"15169","DOI":"10.1073\/pnas.1105639108","volume":"108","author":"JE Deane","year":"2011","unstructured":"Deane JE, Graham SC, Kim NN, Stein PE, McNair R, Cach\u00f3n-Gonz\u00e1lez MB, et al. Insights into Krabbe disease from structures of galactocerebrosidase. Proc Natl Acad Sci U S A. 2011;108:15169\u201373.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"713_CR85","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.ymgme.2016.12.008","volume":"120","author":"EH Schuchman","year":"2017","unstructured":"Schuchman EH, Desnick RJ. Types A and B Niemann-Pick Disease. Mol Genet Metab. 2017;120:27\u201333.","journal-title":"Mol Genet Metab"},{"key":"713_CR86","doi-asserted-by":"publisher","first-page":"1150","DOI":"10.15252\/embr.201643480","volume":"18","author":"W Jung","year":"2017","unstructured":"Jung W, Liu C, Yu Y, Chang Y, Lien W, Chao H, et al. Lipophagy prevents activity-dependent neurodegeneration due to dihydroceramide accumulation in vivo. EMBO Rep. 2017;18:1150\u201365.","journal-title":"EMBO Rep"},{"key":"713_CR87","doi-asserted-by":"crossref","unstructured":"Pant DC, Dorboz I, Schluter A, Fourcade S, Launay N, Joya J, et al. Loss of the sphingolipid desaturase DEGS1 causes hypomyelinating leukodystrophy.\u00a0J Clin Invest. 2019;129:1240\u201356.","DOI":"10.1172\/JCI123959"},{"key":"713_CR88","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1016\/j.immuni.2023.01.008","volume":"56","author":"T Shimizu","year":"2023","unstructured":"Shimizu T, Schutt CR, Izumi Y, Tomiyasu N, Omahdi Z, Kano K, et al. Direct activation of microglia by \u03b2-glucosylceramide causes phagocytosis of neurons that exacerbates Gaucher disease. Immunity. 2023;56:307-319.e8.","journal-title":"Immunity"},{"key":"713_CR89","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.neuron.2017.12.012","volume":"97","author":"F Zunke","year":"2018","unstructured":"Zunke F, Moise AC, Belur NR, Gelyana E, Stojkovska I, Dzaferbegovic H, et al. Reversible conformational conversion of \u03b1-synuclein into toxic assemblies by glucosylceramide. Neuron. 2018;97:92-107.e10.","journal-title":"Neuron"},{"key":"713_CR90","doi-asserted-by":"publisher","first-page":"11854","DOI":"10.1021\/acsnano.1c02957","volume":"15","author":"A Paul","year":"2021","unstructured":"Paul A, Jacoby G, Laor Bar-Yosef D, Beck R, Gazit E, Segal D. Glucosylceramide associated with Gaucher Disease forms amyloid-like twisted ribbon fibrils that induce \u03b1-synuclein Aggregation. ACS Nano. 2021;15:11854\u201368.","journal-title":"ACS Nano"},{"key":"713_CR91","doi-asserted-by":"publisher","first-page":"1807","DOI":"10.1038\/s41467-021-22113-3","volume":"12","author":"S Kim","year":"2021","unstructured":"Kim S, Wong YC, Gao F, Krainc D. Dysregulation of mitochondria-lysosome contacts by GBA1 dysfunction in dopaminergic neuronal models of Parkinson\u2019s disease. Nat Commun. 2021;12:1807.","journal-title":"Nat Commun"},{"key":"713_CR92","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1111\/jnc.15044","volume":"158","author":"M Alaamery","year":"2021","unstructured":"Alaamery M, Albesher N, Aljawini N, Alsuwailm M, Massadeh S, Wheeler MA, et al. Role of sphingolipid metabolism in neurodegeneration. J Neurochem. 2021;158:25\u201335.","journal-title":"J Neurochem"},{"key":"713_CR93","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1002\/mds.25729","volume":"29","author":"SK Abbott","year":"2014","unstructured":"Abbott SK, Li H, Mu\u00f1oz SS, Knoch B, Batterham M, Murphy KE, et al. Altered ceramide acyl chain length and ceramide synthase gene expression in Parkinson\u2019s disease. Mov Disord. 2014;29:518\u201326.","journal-title":"Mov Disord"},{"key":"713_CR94","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0073094","volume":"8","author":"MM Mielke","year":"2013","unstructured":"Mielke MM, Maetzler W, Haughey NJ, Bandaru VVR, Savica R, Deuschle C, et al. Plasma ceramide and glucosylceramide metabolism is altered in sporadic Parkinson\u2019s Disease and associated with cognitive impairment: a pilot study. PLoS ONE. 2013;8: e73094.","journal-title":"PLoS ONE"},{"key":"713_CR95","doi-asserted-by":"publisher","first-page":"145","DOI":"10.2147\/nedt.2007.3.1.145","volume":"3","author":"C Pellicano","year":"2007","unstructured":"Pellicano C, Benincasa D, Pisani V, Buttarelli FR, Giovannelli M, Pontieri FE. Prodromal non-motor symptoms of Parkinson\u2019s disease. Neuropsychiatr Dis Treat. 2007;3:145\u201352.","journal-title":"Neuropsychiatr Dis Treat"},{"key":"713_CR96","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1016\/j.neubiorev.2016.07.010","volume":"68","author":"AA Moustafa","year":"2016","unstructured":"Moustafa AA, Chakravarthy S, Phillips JR, Gupta A, Keri S, Polner B, et al. Motor symptoms in Parkinson\u2019s disease: a unified framework. Neurosci Biobehav Rev. 2016;68:727\u201340.","journal-title":"Neurosci Biobehav Rev"},{"key":"713_CR97","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1186\/1743-0003-2-20","volume":"2","author":"I Amende","year":"2005","unstructured":"Amende I, Kale A, McCue S, Glazier S, Morgan JP, Hampton TG. Gait dynamics in mouse models of Parkinson\u2019s disease and Huntington\u2019s disease. J Neuroengineering Rehabil. 2005;2:20.","journal-title":"J Neuroengineering Rehabil"},{"key":"713_CR98","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0162367","volume":"11","author":"M Dai","year":"2016","unstructured":"Dai M, Liou B, Swope B, Wang X, Zhang W, Inskeep V, et al. Progression of behavioral and CNS deficits in a viable murine model of chronic neuronopathic Gaucher Disease. PLoS ONE. 2016;11: e0162367.","journal-title":"PLoS ONE"},{"key":"713_CR99","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1016\/j.tins.2019.05.010","volume":"42","author":"T Farfel-Becker","year":"2019","unstructured":"Farfel-Becker T, Do J, Tayebi N, Sidransky E. Can GBA1-associated parkinson disease be modeled in the mouse? Trends Neurosci. 2019;42:631\u201343.","journal-title":"Trends Neurosci"},{"key":"713_CR100","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/S0165-0270(01)00485-X","volume":"113","author":"PO Fernagut","year":"2002","unstructured":"Fernagut PO, Diguet E, Labattu B, Tison F. A simple method to measure stride length as an index of nigrostriatal dysfunction in mice. J Neurosci Methods. 2002;113:123\u201330.","journal-title":"J Neurosci Methods"},{"key":"713_CR101","doi-asserted-by":"publisher","first-page":"977","DOI":"10.3390\/biom13060977","volume":"13","author":"J Lamontagne-Proulx","year":"2023","unstructured":"Lamontagne-Proulx J, Coulombe K, Morissette M, Rieux M, Calon F, Di Paolo T, et al. Sex and age differences in a progressive synucleinopathy mouse model. Biomolecules. 2023;13:977.","journal-title":"Biomolecules"},{"key":"713_CR102","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1093\/brain\/awz380","volume":"143","author":"T Taguchi","year":"2020","unstructured":"Taguchi T, Ikuno M, Hondo M, Parajuli LK, Taguchi K, Ueda J, et al. \u03b1-Synuclein BAC transgenic mice exhibit RBD-like behaviour and hyposmia: a prodromal Parkinson\u2019s disease model. Brain. 2020;143:249\u201365.","journal-title":"Brain"},{"key":"713_CR103","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1016\/B978-0-444-63855-7.00024-1","volume":"164","author":"RD Prediger","year":"2019","unstructured":"Prediger RD, Schamne MG, Sampaio TB, Moreira ELG, Rial D. Animal models of olfactory dysfunction in neurodegenerative diseases. Handb Clin Neurol. 2019;164:431\u201352.","journal-title":"Handb Clin Neurol"},{"key":"713_CR104","doi-asserted-by":"crossref","unstructured":"Cerri S, Mus L, Blandini F. Parkinson\u2019s Disease in women and men: what\u2019s the difference?\u00a0J Park Dis. 2019;9:501\u201315.","DOI":"10.3233\/JPD-191683"},{"key":"713_CR105","doi-asserted-by":"publisher","first-page":"2261","DOI":"10.1007\/s10072-021-05230-1","volume":"42","author":"Q Li","year":"2021","unstructured":"Li Q, Jing Y, Lun P, Liu X, Sun P. Association of gender and age at onset with glucocerebrosidase associated Parkinson\u2019s disease: a systematic review and meta-analysis. Neurol Sci. 2021;42:2261\u201371.","journal-title":"Neurol Sci"},{"key":"713_CR106","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1002\/mds.27989","volume":"35","author":"T Simuni","year":"2020","unstructured":"Simuni T, Brumm MC, Uribe L, Caspell-Garcia C, Coffey CS, Siderowf A, et al. Clinical and dopamine transporter imaging characteristics of leucine- rich repeat kinase 2 (LRRK2) and glucosylceramidase beta (GBA) Parkinson\u2019s Disease participants in the Parkinson\u2019s Progression Markers Initiative: a cross-sectional study. Mov Disord Off J Mov Disord Soc. 2020;35:833\u201344.","journal-title":"Mov Disord Off J Mov Disord Soc"},{"key":"713_CR107","doi-asserted-by":"publisher","first-page":"343","DOI":"10.3390\/cells12030343","volume":"12","author":"E Brunialti","year":"2023","unstructured":"Brunialti E, Villa A, Toffoli M, Lucas Del Pozo S, Rizzi N, Meda C, et al. sex-specific microglial responses to glucocerebrosidase inhibition: relevance to GBA1-Linked Parkinson\u2019s Disease. Cells. 2023;12:343.","journal-title":"Cells"}],"container-title":["Molecular Neurodegeneration"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13024-024-00713-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13024-024-00713-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13024-024-00713-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,10]],"date-time":"2024-03-10T22:03:27Z","timestamp":1710108207000},"score":1,"resource":{"primary":{"URL":"https:\/\/molecularneurodegeneration.biomedcentral.com\/articles\/10.1186\/s13024-024-00713-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,7]]},"references-count":107,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["713"],"URL":"https:\/\/doi.org\/10.1186\/s13024-024-00713-z","relation":{},"ISSN":["1750-1326"],"issn-type":[{"value":"1750-1326","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,7]]},"assertion":[{"value":"28 June 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 February 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 March 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All experimental protocols were approved by the Ethics Committee of the University of Padova and authorised by the Italian Ministry of Health (285\/2018-PR).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All authors have read and approved the final manuscript.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"All authors declare no conflict of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"22"}}